Comparative Pharmacology
Head-to-head clinical analysis: MD 76 versus RENO DIP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 76 versus RENO DIP.
MD-76 vs RENO-DIP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-76 is a contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast between vascular structures and surrounding tissues. It distributes in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
RENO-DIP (dipyridamole) is a platelet aggregation inhibitor that inhibits adenosine deaminase and phosphodiesterase, leading to increased intracellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and blocks adenosine reuptake, resulting in vasodilation and inhibition of platelet aggregation.
IV: 50-100 mL per dose, administered as a bolus or infusion, not to exceed 3 mL/kg total dose.
Hypertension: initial 10 mg orally once daily, titrate to 40 mg once daily. Heart failure: initial 2.5 mg orally twice daily, titrate to 20 mg twice daily as tolerated.
None Documented
None Documented
Terminal half-life: 1.5–2 hours; prolonged in renal impairment (up to 20 hours in anuria); clinical context: allows rapid elimination, suitable for diagnostic imaging
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged to 15-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Primarily renal excretion of unchanged drug (70%) via glomerular filtration and active tubular secretion; 20% excreted as metabolites in urine; 10% eliminated in feces via biliary secretion.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent